Biocept Launches Unique Line of Molecular Assay Kits for Detection of Key Oncogene Mutations Based on its Proprietary Target Selectorâ„¢ Technology Validated for Use in Both Tissue and Blood Samples

Biocept Launches Unique Line of Molecular Assay Kits for Detection of Key Oncogene Mutations Based on its Proprietary Target Selectorâ„¢ Technology Validated for Use in Both Tissue and Blood Samples

SAN DIEGO, April 20, 2020 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces the availability of research-use-only (RUO) kits that can allow molecular laboratories around the world to utilize Biocept's Target Selectorâ„¢ molecular assay kits to detect key oncogene mutations through the analysis of both Formalin-Fixed Paraffin-Embedded (FFPE) tissue gained from surgical biopsies as well as circulating tumor DNA (ctDNA) gained from blood-based liquid biopsies.

Biocept's Target Selectorâ„¢ platform is patent protected in the United States, in seven countries in Europe and in five additional international territories.  The first available kits validated for both tissue and blood are for detection of EGFR mutations, which are among the most frequently evaluated biomarkers for lung cancer.  Additional RUO test kits for other oncogene mutations are planned for launch in the future.

Biocept's Target Selectorâ„¢ ctDNA platform utilizes patented Switch-Blocker technology to enrich the specimen for mutations of interest, resulting in ultra-high assay sensitivity and specificity compared to methods currently used in most laboratories.     

"The launch of FFPE capabilities represents a major opportunity for our Target Selectorâ„¢ kits, given the significant market for tissue testing for mutations in solid tumors and the rapid growth in the liquid biopsy segment," said Michael Nall, President and CEO of Biocept.  "Our new dual sample kit offers researchers and assay developers efficiencies and cost savings, including the ability to validate one assay platform for both tissue and blood, and the ability to eliminate the need for macro-dissection for FFPE samples.  In addition, with FFPE samples, QNS (quantity not sufficient) can prevent labs from obtaining biomarker results.  Based on the assay's ability to work with extremely low tumor input and small tissue samples, Target Selectorâ„¢ may provide a result when other FFPE assays are unable to do so."

About Target Selectorâ„¢ ctDNA Kits
Target Selectorâ„¢ molecular assay kits are marketed for research use only and utilize Biocept's proprietary and patented Switch-Blocker technology to enable industry-leading sensitivity for the detection of mutations/variants of interest in ctDNA (one mutant copy in 10,000 wildtype DNA).

Due to its industry-leading sensitivity and the ability to block DNA amplification from normal cells, we believe Target Selectorâ„¢ should allow laboratories to eliminate macro-dissection of tumor blocks, which can result in major workflow improvements and cost savings in the pathology laboratory.  Target Selectorâ„¢ assays can also provide results with small DNA inputs (minimum 4.6 ng), compared to most tissue-based assays, thus allowing the laboratory to get results even with small amounts of tissue.

The Target Selectorâ„¢ assays can be used in combination with a variety of low-cost analytical platforms including qPCR, Sanger sequencing, microarrays, and mass-spectrometry, in addition to next generation sequencing.  Target Selectorâ„¢ kits offer high content per assay, which can reduce costs by selectively amplifying multiple mutations/variants in hot-spot regions of interest in a single reaction.  All Target Selectorâ„¢ assays are quantitative.

For more information on Biocept's Target Selectorâ„¢ liquid biopsy kits, or to order Assay Kits, please contact Biocept Customer Service at (888) 332-7729 or go to customerservice@biocept.com.

About Biocept
Biocept, Inc. is a molecular diagnostics company with commercialized assays for lung, breast, gastric, colorectal and prostate cancers, and melanoma. The Company uses its proprietary liquid biopsy technology to provide physicians with clinically actionable information for treating and monitoring patients diagnosed with cancer. The Company's patented Target Selectorâ„¢ liquid biopsy technology platform captures and analyzes tumor-associated molecular markers in both circulating tumor cells (CTCs) and in circulating tumor DNA (ctDNA). With thousands of tests performed, the platform has demonstrated the ability to identify cancer mutations and alterations to inform physicians about a patient's disease and therapeutic options. For additional information, please visit www.biocept.com.

Forward-Looking Statements Disclaimer Statement
This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance that such expectations and assumptions will prove to have been correct. Forward-looking statements are generally identifiable by the use of words like "may," "will," "should," "could," "expect," "anticipate," "estimate," "believe," "intend," or "project" or the negative of these words or other variations on these words or comparable terminology. To the extent that statements in this release are not strictly historical, including without limitation statements as to our ability to improve the outcomes of patients diagnosed with cancer, our ability to launch additional RUO test kits for other oncogene mutations in the future, the market opportunity for our Target Selectorâ„¢ kits, the ability of our Target Selectorâ„¢ kits to offer research laboratories a number of efficiencies and cost savings, the ability of our Target Selectorâ„¢ kits to provide a result when other FFPE assays may be unable to do so, and our ability to provide physicians with clinically actionable information for treating and monitoring patients diagnosed with cancer, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous risk factors as set forth in our Securities and Exchange Commission (SEC) filings. The effects of such risks and uncertainties could cause actual results to differ materially from the forward-looking statements contained in this release. We do not plan to update any such forward-looking statements and expressly disclaim any duty to update the information contained in this press release except as required by law. Readers are advised to review our filings with the SEC, which can be accessed over the Internet at the SEC's website located at www.sec.gov.

Investor Contact: 
LHA Investor Relations
Jody Cain
Jcain@lhai.com 
310-691-7100                                    

Media Contact:
CORE IR
Jules Abraham
julesa@coreir.com
917-885-7378

View original content to download multimedia:http://www.prnewswire.com/news-releases/biocept-launches-unique-line-of-molecular-assay-kits-for-detection-of-key-oncogene-mutations-based-on-its-proprietary-target-selector-technology-validated-for-use-in-both-tissue-and-blood-samples-301043160.html

SOURCE Biocept, Inc.